102097-81-4

Basic information

• Product Name: methyl 5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridinecarboxylate
• CAS NO: 102097-81-4
• Molecular Weight: 436.401
• Mol File: 102097-81-4.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: methyl 5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridinecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridinecarboxylate(102097-81-4)
• EPA Substance Registry System: methyl 5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridinecarboxylate(102097-81-4)

Safety Data

• Hazardous Substances Data: 102097-81-4(Hazardous Substances Data)

Upstream product

• 115578-86-4 (E)-2,2-dimethyl-1,3-propanediyl α-acetyl-3-nitrostyrylphosphonate 
• 14205-39-1 methyl 3-aminocrotonate 
• 111011-78-0 5,5-dimethyl-2-<1-(3-nitrophenyl)-3-oxo-1-buten-2-yl>-2-oxo-1,3,2-dioxaphosphorinane 
• 1005-69-2 2-methoxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 
• 2428-06-0 2-chloro-5,5-dimethyl-[1,3,2]dioxaphosphinane 
• 111011-80-4 2-acetonyl-5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinane 
• 126-30-7 2,2-Dimethyl-1,3-propanediol 

Relevant articles and documents

Synthesis of 1,4-dihydropyridine-5-phosphonates and their calcium-antagonistic and antihypertensive activities

The effect of the 3-carboxylic-ester variation in 2,2-dimethyltrimethylene 3-alkoxycarbonyl-4-aryl-1,4-dihydro-2,6-dimethyl-5-pyridinephosphonate s (1) was investigated with relation to the calcium-antagonistic and antihypertensive activities: the analogs containing the alkyl groups of not more than 12 carbons and an amino functionality in the carboxylic-ester moiety were synthesized to be examined for biological activities. Among them, 2-[benzyl(phenyl)amino]-ethyl 5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-di methyl-4-(3-nitrophenyl)-3-pyridine-carboxylate hydrochloride ethanol (NZ-105) showed particularly beneficial activities and was selected for further pharmacological studies and clinical development. Some aspects of the structure-activity relationships and solid-state structure of NZ-105 by X-ray crystallographic analysis were described.